Consequently, a downward trend in prices of medicinal products in some countries could contribute to similar downward trends elsewhere, including in the U.S
All entries for: Neurocrine Biosciences Inc
February 11, 2026
Neurocrine Biosciences Inc
Negative Outlook
San Diego, CA
1,000-5,000 employees
Most recently, in August 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law… Lower negotiated prices for AUSTEDO and AUSTEDO XR may increase competitive pressures on INGREZZA, including heightened pricing pressure and potential adverse effects on formulary coverage.
Disease Area: Endocrinology, Multiple, Neurological Diseases, Psychiatry
Drug Type: Biologic, Small Molecule
February 11, 2026
Neurocrine Biosciences Inc
Neutral Outlook
San Diego, CA
1,000-5,000 employees
The current administration has announced agreements with several pharmaceutical companies that require the drug manufacturers to offer, through a direct-to-consumer platform, U.S. patients and Medicaid programs prescription drug Most-Favored Nation pricing equal to or lower than those paid in other developed nations, with additional mandates for direct-to-patient discounts and repatriation of foreign revenues.
October 28, 2025
Neurocrine Biosciences Inc
Negative Outlook
San Diego, CA
1,000-5,000 employees
Enacted healthcare reform, drug pricing measures and other recent legislative initiatives, including the Inflation Reduction Act of 2022 (IRA), could adversely affect our business.
Disease Area: Endocrinology, Multiple, Neurological Diseases, Psychiatry
Drug Type: Biologic, Small Molecule
July 30, 2025
Neurocrine Biosciences Inc
Neutral Outlook
San Diego, CA
1,000-5,000 employees
AUSTEDO and AUSTEDO XR, marketed by Teva Pharmaceuticals Industries, have been selected for the Medicare drug negotiation program in 2025 (for initial price applicability year 2027). If the negotiation program results in a decrease in the price of AUSTEDO or AUSTEDO XR, it may result in increased competitive pressure on INGREZZA. We were notified in January 2025 that INGREZZA qualifies for the small biotech exception, which provides an exemption from selection until 2027 (for initial price applicability year 2029, pursuant to which negotiated pricing would go into effect, if selected). If negotiated for initial price applicability year 2029, we expect that the negotiated price for INGREZZA would be constrained by the “short monopoly” price ceiling and temporary price floor for small biotech drugs.
Disease Area: Endocrinology, Multiple, Neurological Diseases, Psychiatry
Drug Type: Biologic, Small Molecule